{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-008250","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.844390+00:00","generated_at":"2026-06-17T23:19:30.971584+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sanara MedTech FY2022 revenue $45.8M (+90% YoY); net loss $8.1M","bullets":["Net revenue $45.8M vs $24.1M in 2021, a 90% increase; gross margin 86% vs 90%.","Net loss $8.1M vs $8.0M in 2021; SG&A expenses rose to $46.0M from $28.1M.","CellerateRX sold in over 700 facilities across 29 states; generated >$5M revenue in a single month.","Entered partnership with InfuSystem for wound care; filed 510(k) for BIASURGE and Precision Healing Imager.","Entered ATM sales agreement with Cantor Fitzgerald for stock offerings."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-008250","json":"https://secwatch.observer/filing/0001493152-23-008250.json","markdown":"https://secwatch.observer/filing/0001493152-23-008250.md","text":"https://secwatch.observer/filing/0001493152-23-008250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/0001493152-23-008250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:19:30.971584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70047ed875c8e849aa19a504bdd985168210b668","claim":"Sanara MedTech Inc. reported the quarter and year ended December 31, 2022 results: revenue $45.8 million.","evidence_excerpt":"for its Precision Healing Multispectral Imager Full Year 2022 Consolidated Financial Results ● Net Revenues. For the year ended December 31, 2022, we generated net revenues of $45.8 million compared to net revenues of $24.1 million for the year ended December 31, 2021, a 90% increase from the prior year. Our 2022 net revenues included $6.0 million of Scendia","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/0001493152-23-008250-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$45.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}